Publication date: Jul 06, 2023
Current treatments modalities for major depressive disorder (MDD) mainly target monoaminergic neurotransmission. However, the therapeutic inadequacy and adverse effects confine the use of these conventional antidepressants to a limited subset of patients with MDD. Classic antidepressants are increasingly proving unsatisfactory in tackling treatment-resistant depression (TRD). Hence, the focus of treatment is shifting to alternative pathogenic pathways involved in depression. Preclinical and clinical evidence unequivocally affirmed the causative role of immuno-inflammatory pathways in the progression of depression, resulting in an increase in the clinical evaluation of drugs with anti-inflammatory effects being used as antidepressants. In this review, we highlight the molecular mechanisms connecting inflammatory pathways to MDD and the current clinical status of inflammation-modulating drugs for the treatment of MDD.
|disease||MESH||major depressive disorder|